Bone and paraproteinemias

Current Opinion in Supportive and Palliative Care

Volumn 4, Issue 3, 2010, Pages 195-199

  Zangari, Maurizio ^a   Zhan, Fenghuang ^a   Tricot, Guido ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Bone; Monoclonal gammopathy of undetermined significance; Myeloma; Proteasome

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE; BONE TUMOR; HUMAN; METABOLISM; MULTIPLE MYELOMA; PARAPROTEINEMIA; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PROGNOSIS; RISK FACTORS;

EID: 78449278928     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32833d3011     Document Type: Article

References (48)

1. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004; 32:290-292
2. Melton LJ III, Kyle RA, Achenbach SJ, et al. Fracture risk with multiple myeloma: A population-based study. J Bone Miner Res 2005; 20:487-493
3. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006; 107:904-906
4. Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113:5418-5422. Preexisting plasma cell disorders, monoclonal gammopathy of undetermined significance, or smoldering myeloma are present in at least one-third of multiple myeloma patients. However, the proportion of patients with a preexisting plasma cell disorder was not previously determined by laboratory testing on prediagnostic sera. The presence of monoclonal was detected in 27 of 30 patients by serum protein electrophoresis and/or immunofixation electrophoresis in 21 patients only by serum-free light-chain analysis in six patients
5. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362-1369
6. Vachon CM, Kyle RA, Therneau TM, et al. Increased risk of monoclonal gammopathy of undetermined significance. Blood 2009; 114:785-790. This study examined whether MGUS is increased in first-degree relatives of multiple myeloma or MGUS patients. The prevalence of MGUS in relatives was compared with population-based rates. By electrophoresis, MGUS was detected in 55 (6%) of relatives and immunofixation identified 28 additional relatives for an age-adjusted and sex-adjusted prevalence of 8.1%. The increased risk was seen among relatives of multiple myeloma (RR, 2.0; 95% CI, 1.4-2.8) and MGUS probands (RR, 3.3; 95% CI, 2.1-4.8). The increased risk of MGUS in first-degree relatives of MGUS or multiple myeloma patients implies shared environment and/or genetics
7. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362-1369
8. Singh J, Dudley AW Jr, Kulig KA. Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting. J Lab Clin Med 1990; 116:785-789
9. Melton LJ III, Rajkumar SV, Khosla S, et al. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004; 19:25-30
10. Pepe J, Petrucci MT, Nofroni I, et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134:485-490
11. Bida JP, Kyle RA, Therneau TM, et al. Disease associations with monoclonal gammopathy of undetermined significance: A population based study of 17 398 patients. Mayo Clinic Proc 2009; 84:685-693. To systematically study the association of MGUS with all diseases in a populationbased cohort of 17 398 patients, all of whom were uniformly tested for the presence or absence of MGUS. The analysis confirmed a significant association in 14 (19%) of the 75 previously reported disease associations with MGUS, including vertebral and hip fractures, and osteoporosis
12. Politou M, Terpos E, Anagnostopoulos A, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004; 126:686-689
13. Jakob C, Zavrski I, Heider U, et al. Bone resorption parameters [carboxyterminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 2002; 69:37-42
14. Mundy GR, Raisz LG, Cooper RA, et al. Evidence for the secretion of an osteoclast stimulating factor inmyeloma.NEngl JMed1974; 291:1041-1046
15. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts in the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991; 88:62-66
16. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. PNAS 2001; 98:11581-11586
17. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127:469-480
18. Lee JW, Chung HY, Ehrlich LA, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004; 103:2308-2315
19. Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 2005; 65:1700-1709
20. Kukreja A, Hutchinson A, Dhodapkar K, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006; 203:1859-1865
21. Dhodapkar KM, Barbuto S, Matthews P, et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008; 112:2878-2885
22. Ehrlich LA, Roodman GD. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Immunol Rev 2005; 208:252-266
23. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98:3527-3533
24. Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8:751-764
25. Qiang YW, Chen Y, Stephens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008; 112:196-207
26. Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target. Cancer Cell 2009; 16:309-323. Using both in-vitro and in-vivo multiple myeloma xenograft models, the paper shows that plasmacytoid dendritic cells (pDCs) in the bone marrow microenvironment both mediate immune deficiency characteristic of multiple myeloma and promote multiple myeloma cell growth, survival, and drug resistance. The study validates targeting pDC-multiple myeloma interactions as a therapeutic strategy to overcome drug resistance in multiple myeloma
27. Wong BR, Josien R, Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 1999; 65:715-724
28. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349:2483-2494
29. Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106:2472-2483
30. Standal T, Abildgaard N, Fagerli UM, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002; 100:3002-3007
31. Yaccoby S, Wezeman MJ, Zangari M, et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and myelomatous mouse model. Haematologica 2006; 91:192-199
32. Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood 2008; 112:159-168
33. Vallet S, Mukherjee S, Vaghela N. Activin A promotes multiple myelomainduced osteolysis and is a promising target for myeloma bone disease. PNAS 2010; 107:2124-5129. Activin A, a TGF-b family member, is a therapeutically amenable target exploited by multiple myeloma to alter its microenvironmental niche thus favoring osteolysis. Increased bone marrow plasma activin A levels were found in multiple myeloma patients with osteolytic disease. Multiple myeloma cell engagement of marrow stromal cells enhances activin A secretion via adhesion-mediated JNK activation
34. Snapper I, Khan A. Myelomatosis: Fundamentals and clinical features. Baltimore: University Park Press; 2001
35. Lecouvet FE, Vande Berg BC, Malghem J, Maldague BE. Magnetic resonance and computed tomography imaging in multiple myeloma. Semin Musculoskelet Radiol 2001; 5:43-55
36. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications. J Clin Oncol 2007; 25:1121-1128
37. Dimopoulos MA, Moulopoulos LA, Datseris I, et al. Imaging of myeloma bone disease-implications for staging prognosis and follow-up. Acta Oncol 2000; 39:823-827
38. Bartel TB, Haessler J, Brown TLY, et al. F18-fluorodeoxyglucose positron tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009; 114:2068-2076. FDG-PET is a powerful tool to investigate the role of tumor metabolic activity and its suppression by therapy for cancer survival. Metastatic bone survey, MRI, and FDG-PET scanning were evaluated in 239 untreated patients. Complete FDG suppression in focal lesion, before first transplantation, conferred significantly better outcomes. This study provides a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction therapy
39. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16:593-602
40. Rosen LS, Gordon D, Kaminiski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001; 7:377-387
41. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline updated on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25:2464-2472
42. Khosla S, Brr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479-1491
43. Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003; 111:1771-1782
44. Pennisi A, Li X, Ling W, et al. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009; 84:6-14. The ubiquitin-proteasome pathway regulates differentiation of bone cells and multiple myeloma cell growth. Antimyeloma response of bortezomib, which was evident in more than 50% of 16 experiments and resembled clinical responses, was associated with significant increased BMD and osteoblast numbers, and reduced osteoclast numbers in myelomatous bones. This study indicates that bone disease is both a consequence and necessity of multiple myeloma progression, and results suggest that bortezomib's effects on bone remodeling contribute to the antimyeloma efficacy of this drug
45. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib in associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005; 131:71-73 (Pubitemid 43899710)
46. Zangari M, Esseltine D, Cavallo F, et al. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol 2007; 82:831-833
47. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf- 1 and receptor activator of nuclear factor-kappab ligand concentrations and normalizes indices of bone remodeling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135:688-692
48. Zangari M, Cavallo F, Suva L, et al (2007). Prospective evaluation of the bone anabolic effect of bortezomib in relapsed multiple myeloma (MM) patients [abstract]. Blood 110: Abstract # 198.